Iijima T - Search Results

1

Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Shimizu M, et al. Among authors: iijima t, iijima m. Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2. Diabetes Obes Metab. 2019. PMID: 30178600 Clinical Trial.

2

Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients.

Kawagoe Y, Hattori Y, Nakano A, Aoki C, Tanaka S, Ohta S, Iijima T, Tomizawa A, Jojima T, Kase H, Kasai K. Kawagoe Y, et al. Among authors: iijima t. Endocr J. 2011;58(3):171-5. doi: 10.1507/endocrj.k10e-289. Epub 2011 Feb 4. Endocr J. 2011. PMID: 21304215 Free article. Clinical Trial.

3

The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes.

Aso Y, Terasawa T, Kato K, Jojima T, Suzuki K, Iijima T, Kawagoe Y, Mikami S, Kubota Y, Inukai T, Kasai K. Aso Y, et al. Among authors: iijima t. Transl Res. 2013 Nov;162(5):309-16. doi: 10.1016/j.trsl.2013.07.011. Epub 2013 Aug 30. Transl Res. 2013. PMID: 23994650 Clinical Trial.

4

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.

Aso Y, Jojima T, Iijima T, Suzuki K, Terasawa T, Fukushima M, Momobayashi A, Hara K, Takebayashi K, Kasai K, Inukai T. Aso Y, et al. Among authors: iijima t. Endocrine. 2015 Dec;50(3):659-64. doi: 10.1007/s12020-015-0688-5. Epub 2015 Jul 25. Endocrine. 2015. PMID: 26209038 Clinical Trial.

5

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.

Aso Y, Fukushima M, Sagara M, Jojima T, Iijima T, Suzuki K, Momobayashi A, Kasai K, Inukai T. Aso Y, et al. Among authors: iijima t. Diabetes Res Clin Pract. 2015 Dec;110(3):250-6. doi: 10.1016/j.diabres.2015.10.012. Epub 2015 Oct 20. Diabetes Res Clin Pract. 2015. PMID: 26508675 Clinical Trial.

6

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.

Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Jojima T, et al. Among authors: iijima t. Diabetol Metab Syndr. 2016 Jul 26;8:45. doi: 10.1186/s13098-016-0169-x. eCollection 2016. Diabetol Metab Syndr. 2016. PMID: 27462372 Free PMC article.

7

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.

Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y. Jojima T, et al. Among authors: iijima t. Atherosclerosis. 2017 Jun;261:44-51. doi: 10.1016/j.atherosclerosis.2017.04.001. Epub 2017 Apr 7. Atherosclerosis. 2017. PMID: 28445811

8

Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells.

Iijima T, Kato K, Jojima T, Tomotsune T, Fukushima M, Suzuki K, Aso Y. Iijima T, et al. Diabetes Res Clin Pract. 2017 Nov;133:10-12. doi: 10.1016/j.diabres.2017.07.036. Epub 2017 Jul 31. Diabetes Res Clin Pract. 2017. PMID: 28869918

9

Concurrent variant type 3 autoimmune polyglandular syndrome and pulmonary arterial hypertension in a Japanese woman.

Iijima T, Niitani T, Tanaka S, Yanagi K, Jojima T, Suzuki K, Usui I, Aso Y. Iijima T, et al. Endocr J. 2018 Apr 26;65(4):493-498. doi: 10.1507/endocrj.EJ17-0465. Epub 2018 Feb 16. Endocr J. 2018. PMID: 29459556 Free article.

10

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T, Iijima T, Maejima Y, Shimomura K, Usui I. Aso Y, et al. Among authors: iijima t. Int J Clin Pract. 2019 May;73(5):e13335. doi: 10.1111/ijcp.13335. Epub 2019 Apr 1. Int J Clin Pract. 2019. PMID: 30810254 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,054 results

Search Page

Filters